NCT04064905

Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults

A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 120 (actual)
• Sponsor: ModernaTX, Inc. · Industry
• Sex: All
• Age: 18 Years – 49 Years
• Healthy volunteers: Accepted

Summary

This clinical study will evaluate the safety, tolerability and reactogenicity of mRNA-1893 Zika vaccines in flavivirus seronegative and flavivirus seropositive participants

Conditions

• Zika Virus

Interventions

Type	Name	Description
BIOLOGICAL	mRNA-1893	Zika vaccine
OTHER	Placebo	0.9% sodium chloride

Timeline

• Start date: 2019-07-30
• Primary completion: 2021-03-22
• Completion: 2021-03-22
• First posted: 2019-08-22
• Last updated: 2024-08-21
• Results posted: 2024-06-17

Locations

4 sites across 2 countries: United States, Puerto Rico

Regulatory

• FDA-regulated drug study